PubRank

J R Kalden

Author PubWeight™ 335.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 16.20
2 Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 8.69
3 Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994 7.04
4 Immunosuppressive effects of apoptotic cells. Nature 1997 7.03
5 Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999 5.00
6 A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003 4.86
7 Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005 4.28
8 Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002 3.53
9 Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998 3.41
10 Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997 3.29
11 Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004 3.00
12 A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res 1994 2.96
13 Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol 1999 2.74
14 Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis 2001 2.69
15 EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004 2.48
16 Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis 2008 2.45
17 In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum 1997 1.95
18 Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998 1.93
19 Activated T cells in vivo and in vitro: divergence in expression of Tac and Ia antigens in the nonblastoid small T cells of inflammation and normal T cells activated in vitro. J Immunol 1984 1.87
20 A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum 1999 1.85
21 Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001 1.78
22 Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005 1.77
23 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007 1.70
24 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis 2012 1.67
25 Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. Arthritis Rheum 1995 1.66
26 Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003 1.64
27 Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995 1.63
28 Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. Ann Rheum Dis 2001 1.63
29 The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001 1.62
30 SLE--a disease of clearance deficiency? Rheumatology (Oxford) 2005 1.59
31 Single-photon-emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993 1.53
32 Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol 1990 1.52
33 Studies on experimental autoimmune thymitis in guinea-pigs. Clin Exp Immunol 1969 1.50
34 Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992 1.48
35 In vitro and in vivo effect of glucocorticoids on IgE and IgG subclass secretion. Clin Exp Allergy 1994 1.47
36 Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004 1.47
37 Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation 2001 1.46
38 Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 1991 1.45
39 CD4 positive peripheral T cells from patients with systemic lupus erythematosus (SLE) are clonally expanded. Lupus 2001 1.44
40 Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 2002 1.39
41 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010 1.34
42 Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis 2002 1.33
43 Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 2006 1.32
44 The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. I. The localization of the major synovial cell populations as detected by monoclonal reagents directed towards Ia and monocyte-macrophage antigens. Rheumatol Int 1983 1.32
45 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008 1.31
46 Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24 recognized from a long-term nonprogressor: constraints on immune escape associated with targeting a sequence essential for viral replication. J Immunol 1999 1.31
47 Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006 1.29
48 Persistence of Borrelia burgdorferi in ligamentous tissue from a patient with chronic Lyme borreliosis. Arthritis Rheum 1993 1.27
49 Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000 1.26
50 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006 1.25
51 Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis 2003 1.25
52 The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006 1.24
53 Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis 2004 1.24
54 T cell proliferation induced by Borrelia burgdorferi in patients with Lyme borreliosis. Autologous serum required for optimum stimulation. Arthritis Rheum 1991 1.23
55 Central retinal artery occlusion in Sneddon's disease associated with antiphospholipid antibodies. Am J Ophthalmol 1986 1.23
56 In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 1996 1.21
57 After shrinkage apoptotic cells expose internal membrane-derived epitopes on their plasma membranes. Cell Death Differ 2006 1.21
58 Spontaneous cytotoxicity (SCMC) of normal human lymphocytes against a human melanoma cell line: a phenomenon due to a lymphotoxin-like mediator. J Immunol 1976 1.20
59 Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand J Immunol 1978 1.19
60 Differential expression of Ia antigens by rheumatoid synovial lining cells. J Clin Invest 1987 1.18
61 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011 1.17
62 Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001 1.16
63 Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006 1.16
64 Role of apoptosis in autoimmunity. Apoptosis 2000 1.15
65 Thymic myogenesis, T-lymphocytes and the pathogenesis of myasthenia gravis. Ann N Y Acad Sci 1981 1.14
66 Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993 1.13
67 HLA markers and prediction of clinical course and outcome in rheumatoid arthritis. Arthritis Rheum 1997 1.12
68 Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) 2001 1.10
69 Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor. Blood 1991 1.10
70 Major histocompatibility complex haplotypes and complement C4 alleles in systemic lupus erythematosus. Results of a multicenter study. J Clin Invest 1992 1.10
71 [Guideline for the joint swelling symptom--primary physician problem management and referral indications. German Society of Rheumatology "Quality Assurance" Committee]. Z Rheumatol 2000 1.09
72 Modulation of monocyte activation in patients with rheumatoid arthritis by leukapheresis therapy. J Clin Invest 1993 1.09
73 Human pluripotent hemopoietic colony stimulating factor: activities on human and murine cells. Immunobiology 1986 1.09
74 Cellular immune response toward human articular chondrocytes. T cell reactivities against chondrocyte and fibroblast membranes in destructive joint diseases. Arthritis Rheum 1990 1.09
75 Preferential cellular and humoral immune reactivities to native and denatured collagen types IX and XI in a patient with fatal relapsing polychondritis. J Rheumatol 1993 1.08
76 Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis. Ann Rheum Dis 2000 1.08
77 Reduction of monocyte-macrophage activation markers upon anti-CD4 treatment. Decreased levels of IL-1, IL-6, neopterin and soluble CD14 in patients with rheumatoid arthritis. Clin Exp Immunol 1993 1.08
78 Testing for association in SLE families. Genet Epidemiol 1991 1.07
79 Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes. AIDS 2000 1.07
80 Histone-specific Th0 and Th1 clones derived from systemic lupus erythematosus patients induce double-stranded DNA antibody production. Arthritis Rheum 1997 1.07
81 Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. Arthritis Rheum 1997 1.07
82 Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 2001 1.07
83 Clinical relevance of Fc gamma receptor polymorphisms. Ann N Y Acad Sci 1997 1.07
84 Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation. Rheumatology (Oxford) 1999 1.06
85 Changes in cell surface antigen expression on human articular chondrocytes induced by gamma-interferon. Induction of Ia antigens. Arthritis Rheum 1987 1.06
86 Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004 1.06
87 Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis 2003 1.05
88 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013 1.05
89 Autologous and allogeneic MLC-reactivity in patients with rheumatoid arthritis. J Clin Lab Immunol 1981 1.05
90 Biochemical characterization and microsequencing of a 205-kDa synovial protein stimulatory for T cells and reactive with rheumatoid factor containing sera. J Immunol 1996 1.05
91 Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis. Clin Exp Rheumatol 2000 1.04
92 Experimental myasthenia gravis. Lancet 1969 1.03
93 IgG human monoclonal anti-DNA autoantibodies from patients with systemic lupus erythematosus. Clin Exp Immunol 1991 1.02
94 Differential role for IL-2 and IL-15 in the inhibition of apoptosis in short-term activated human lymphocytes. Scand J Immunol 1997 1.02
95 Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol 1999 1.01
96 The effect of hypophysectomy on the immune response. Immunology 1970 1.00
97 IgM anti-dsDNA antibodies in systemic lupus erythematosus: negative association with nephritis. SLE Study Group. Rheumatol Int 1998 1.00
98 Viable, apoptotic and necrotic monocytes expose phosphatidylserine: cooperative binding of the ligand Annexin V to dying but not viable cells and implications for PS-dependent clearance. Cell Death Differ 2005 0.98
99 Interleukin-6 production in B-cell neoplasias and Castleman's disease: evidence for an additional paracrine loop. Ann Hematol 1994 0.98
100 Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 2002 0.98
101 Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T-cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 1998 0.98
102 Leucocyte-migration test in sarcoidosis. Lancet 1972 0.98
103 Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol 2000 0.98
104 Information and participation in decision-making about treatment: a qualitative study of the perceptions and preferences of patients with rheumatoid arthritis. J Med Ethics 2008 0.98
105 HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996 0.97
106 Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum 1998 0.97
107 Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils. J Biol Chem 1998 0.97
108 What triggers anti-dsDNA antibodies? Mol Biol Rep 1996 0.96
109 An anti-CD4 antibody for treatment of chronic inflammatory arthritis. Agents Actions Suppl 1991 0.95
110 Immortalization with herpesvirus saimiri modulates the cytokine secretion profile of established Th1 and Th2 human T cell clones. J Immunol 1993 0.95
111 Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001). Ann Rheum Dis 2001 0.95
112 Distribution of TNF-alpha, TNF-R55 and TNF-R75 in the rheumatoid synovial membrane: TNF receptors are localized preferentially in the lining layer; TNF-alpha is distributed mainly in the vicinity of TNF receptors in the deeper layers. Scand J Immunol 1999 0.94
113 Positive influence of the Delta32CCR5 allele on response to highly active antiretroviral therapy (HAART) in HIV-1 infected patients. Eur J Med Res 2000 0.94
114 The tissue architecture of synovial membranes in inflammatory and non-inflammatory joint diseases. II. The localization of mononuclear cells as detected by monoclonal antibodies directed against T-lymphocyte subsets and natural killer cells. Rheumatol Int 1984 0.94
115 Proposed response criteria for neurocognitive impairment in systemic lupus erythematosus clinical trials. Lupus 2007 0.94
116 CD 95-independent mechanisms of IL-2 deprivation-induced apoptosis in activated human lymphocytes. Cell Death Differ 2000 0.93
117 Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells. Cancer Res 1998 0.93
118 [Hyperferritinemia in Still syndrome in the adult and reactive hemophagocytic syndrome]. Med Klin (Munich) 1997 0.93
119 Constant isotype pattern of anti-dsDNA antibodies in patients with systemic lupus erythematosus. Clin Exp Immunol 1988 0.93
120 Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 2002 0.93
121 FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997 0.93
122 [Vascular changes in the pathogenesis of systemic sclerosis]. Z Rheumatol 2004 0.92
123 IgE-containing circulating immune complexes in Churg-Strauss vasculitis. Scand J Immunol 1985 0.92
124 The analysis of mononuclear cell infiltrations in colorectal adenocarcinoma. J Cancer Res Clin Oncol 1985 0.92
125 Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. Clin Immunol Immunopathol 1991 0.92
126 [Clinical course and prognostic parameters in adult-onset Still's syndrome. Own experience and review of the literature]. Med Klin (Munich) 1997 0.92
127 Increase of intracellular calcium is the essential signal for the expression of CD40 ligand. Eur J Immunol 1996 0.92
128 Extranuclear detection of histones and nucleosomes in activated human lymphoblasts as an early event in apoptosis. Ann Rheum Dis 2004 0.92
129 Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual. J Immunol 1998 0.92
130 Retroviruses and systemic lupus erythematosus. Immunol Rev 1996 0.91
131 IgA and IgG autoantibodies against alpha-fodrin as markers for Sjögren's syndrome. Systemic lupus erythematosus. J Rheumatol 2000 0.91
132 MHC class II expression on myeloid cells inversely correlates with disease progression in early rheumatoid arthritis. Rheumatology (Oxford) 2007 0.91
133 The effect of thymectomy, hemi-thymectomy and sham thymectomy on experimental myasthenia gravis in guinea-pigs. Clin Exp Immunol 1970 0.91
134 Association of HLA-Bw35 with mucocutaneous lesions in rheumatoid arthritis patients undergoing sodium aurothiomalate therapy. Arthritis Rheum 1984 0.91
135 Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study. Ann Rheum Dis 2002 0.91
136 Pregnancy course and complications in patients with systemic lupus erythematosus. Am J Reprod Immunol 1993 0.91
137 NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int 1997 0.91
138 Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 2003 0.90
139 5,6-carboxyfluorescein diacetate succinimidyl ester-labeled apoptotic and necrotic as well as detergent-treated cells can be traced in composite cell samples. Anal Biochem 2001 0.90
140 Prolonged skin allograft survival in vitamin C-deficient guinea-pigs. Preliminary communication. Eur Surg Res 1972 0.90
141 Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 1997 0.90
142 Experimental myasthenia gravis, myositis and myocarditis in guinea-pigs immunized with subcellular fractions of calf thymus or calf skeletal muscle in Freund's complete adjuvant. Clin Exp Immunol 1973 0.89
143 What we have learned from trials of immunomodulatory agents in rheumatoid arthritis: Future directions. Drugs Today (Barc) 2003 0.89
144 Treatment with annexin V increases immunogenicity of apoptotic human T-cells in Balb/c mice. Cell Death Differ 2000 0.89
145 Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999 0.89
146 Circulating immune complexes in HIV-infected persons. Klin Wochenschr 1990 0.89
147 Functional characterization of tumor-infiltrating lymphocytes, lymph-node lymphocytes and peripheral-blood lymphocytes from patients with breast cancer. Int J Cancer 1991 0.88
148 Human peripheral Null lymphocytes. I. Isolation, immunological and functional characterization. Eur J Immunol 1977 0.88
149 CD45 tyrosine phosphatase controls common gamma-chain cytokine-mediated STAT and extracellular signal-related kinase phosphorylation in activated human lymphoblasts: inhibition of proliferation without induction of apoptosis. J Immunol 2001 0.88
150 Plasmapheresis therapy in an elderly patient with rapidly progressive Henoch-Schönlein purpura with disseminated organ involvement. Clin Rheumatol 2006 0.88
151 Antigenicity and accessory cell function of human articular chondrocytes. J Rheumatol 1991 0.87
152 Functional and phenotypical characterization of activated T cells from intra-articular sites in inflammatory joint diseases. Possible modulation of the CD3 antigen. Scand J Immunol 1987 0.87
153 Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. J Immunol 2001 0.87
154 PCR and reverse dot hybridization for the detection of endogenous retroviral transcripts. J Virol Methods 1994 0.87
155 The role of antineutrophil cytoplasm antibodies, anticardiolipin antibodies, von Willebrand factor antigen, and fibronectin for the diagnosis of systemic vasculitis. J Rheumatol 1991 0.87
156 [Long term effects of splenectomy on the immune-status of Hodgkin's disease patients depending on the modality of treatment (author's transl)]. Med Klin 1978 0.87
157 Rheumatoid factors in systemic lupus erythematosus: association with clinical and laboratory parameters. SLE study group. Rheumatol Int 2000 0.87
158 IgG autoantibodies bound to surfaces of necrotic cells and complement C4 comprise the phagocytosis promoting activity for necrotic cells of systemic lupus erythaematosus sera. Ann Rheum Dis 2007 0.86
159 Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener's granulomatosis. Ann Rheum Dis 2005 0.86
160 The pathogenesis of autoimmune diseases. Scand J Clin Lab Invest Suppl 2001 0.86
161 Osteonecrosis in systemic lupus erythematosus, steroid-induced or a lupus-dependent manifestation? Lupus 1996 0.85
162 Immunological characterization of mononuclear cells in peripheral blood and regional lymph nodes of breast cancer patients. Cancer 1979 0.85
163 Up-regulation of MDC15 (metargidin) messenger RNA in human osteoarthritic cartilage. Arthritis Rheum 1999 0.85
164 Humoral and cellular immune reactions 'in vitro' against allogeneic and autologous human melanoma cells. Clin Exp Immunol 1975 0.85
165 UV irradiation inhibits ABC transporters via generation of ADP-ribose by concerted action of poly(ADP-ribose) polymerase-1 and glycohydrolase. Cell Death Differ 2004 0.85
166 Suppression of HHV-8 viremia by foscarnet in an HIV-infected patient with Kaposi's sarcoma and HHV-8 associated hemophagocytic syndrome. Eur J Med Res 1998 0.85
167 [Longterm outcome of TNF blockade in adult-onset Still's disease]. Dtsch Med Wochenschr 2004 0.85
168 Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue. Arthritis Rheum 2001 0.85
169 Antibody-dependent cellular cytotoxicity and B-and T-cell activity in the peripheral blood of myasthenia gravis patients. Ann N Y Acad Sci 1976 0.84
170 UV-B irradiated cell lines execute programmed cell death in various forms. Apoptosis 1998 0.84
171 Anticardiolipin antibodies in HIV infection: association with cerebral perfusion defects as detected by 99mTc-HMPAO SPECT. Clin Exp Immunol 1994 0.84
172 Association of IgA anti-dsDNA antibodies with vasculitis and disease activity in systemic lupus erythematosus. SLE Study Group. Rheumatol Int 1998 0.84
173 Patients with rheumatoid arthritis adapt differently to repetitive painful stimuli compared to healthy controls. J Clin Neurosci 2001 0.84
174 Induction of apoptosis by spermine-metabolites in primary human blood cells and various tumor cell lines. Apoptosis 2005 0.84
175 Influence of different histologic preparation methods on preservation of tissue antigens in the immunofluorescent antibody technique. Ann N Y Acad Sci 1975 0.84
176 Chlorpromazine induces apoptosis in activated human lymphoblasts: a mechanism supporting the induction of drug-induced lupus erythematosus? Arthritis Rheum 2000 0.84
177 Combination of immunoadsorption and CD20 antibody therapy in a patient with mixed connective tissue disease. Rheumatology (Oxford) 2006 0.84
178 Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001 0.84
179 Longitudinal development of distress, coping and quality of life in HIV-positive persons. Psychother Psychosom 1997 0.83
180 High resolution electrophoresis for the allotyping of human C4. Proposal of a relational nomenclature. J Immunol Methods 1987 0.83
181 A simple assay for quantifying the inducible adherence of neutrophils. Immunobiology 1990 0.83
182 HLA DR and DQ RFLP analysis in Crohn's disease. Eur J Immunogenet 1993 0.83
183 In vivo blockade of tumor necrosis factor-alpha in patients with rheumatoid arthritis: longterm effects after repeated infusion of chimeric monoclonal antibody cA2. J Rheumatol 2000 0.83
184 Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis. Nucl Med Commun 1993 0.83
185 Cartilage-specific autoimmunity in rheumatoid arthritis: characterization of a triple helical B cell epitope in the integrin-binding-domain of collagen type II. Eur J Immunol 2001 0.83
186 Prospective analysis of the impact of HLA-DR and -DQ on joint destruction in recent-onset rheumatoid arthritis. Rheumatology (Oxford) 2003 0.83
187 Detection of restricted junctional diversity of peripheral T cells in SLE patients by spectratyping. Lupus 1997 0.83
188 Regulation of granulocyte macrophage colony stimulating factor production by human articular chondrocytes. Induction by both tumor necrosis factor-alpha and interleukin 1, downregulation by transforming growth factor beta and upregulation by fibroblast growth factor. J Rheumatol 1994 0.83
189 Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis 1999 0.83
190 Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int J Immunopathol Pharmacol 2006 0.83
191 Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology (Oxford) 2000 0.82
192 [Arthroosteitis pustulosa, spondarthritis hyperostotica pustulo-psoriatica, SAPHO syndrome: clinical experiences and review of the literature]. Z Rheumatol 1994 0.82
193 Animal models of autoimmune diseases. Rheumatol Int 1997 0.82
194 123I-antileukoproteinase scintigraphy reveals microscopic cartilage alterations in the contralateral knee joint of rats with "monarticular" antigen-induced arthritis. Arthritis Rheum 2000 0.82
195 Autoimmune rat T lymphocytes monospecific for acetylcholine receptors: purification and fine specificity. J Immunol 1981 0.82
196 Antineutrophil cytoplasmic autoantibodies (ANCA) recognizing a recombinant myeloperoxidase subunit. Adv Exp Med Biol 1993 0.82
197 CEA-containing immune complexes in sera of patients with colorectal and breast cancer--analysis of complexed immunoglobulin classes. Cancer Immunol Immunother 1988 0.82
198 Antibody binding of macromolecular DNA and RNA in the plasma of SLE patients. Clin Exp Immunol 1989 0.82
199 CD45 mAb induces cell adhesion in peripheral blood mononuclear cells via lymphocyte function-associated antigen-1 (LFA-1) and intercellular cell adhesion molecule 1 (ICAM-1). Cell Immunol 1993 0.82
200 Comparative analysis of sequence variability in the upstream regulatory region of the HLA-DQB1 gene. Immunogenetics 1994 0.82
201 Microparticles shed from different antigen-presenting cells display an individual pattern of surface molecules and a distinct potential of allogeneic T-cell activation. Scand J Immunol 2005 0.82
202 Elevated levels of circulating tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 in systemic reactions induced by anti-CD4 therapy in patients with rheumatoid arthritis. Cytokine 1991 0.81
203 Retrovirus-associated rheumatic syndromes. Curr Opin Rheumatol 1998 0.81
204 Alpha-lipoic acid is an effective inhibitor of human immuno-deficiency virus (HIV-1) replication. Klin Wochenschr 1991 0.81
205 Safety of 15-deoxyspergualin in the treatment of glomerulonephritis associated with active systemic lupus erythematosus. Ann Rheum Dis 2005 0.81
206 The role of the transferrin receptor for the activation of human lymphocytes. Cell Immunol 1991 0.81
207 Immune mechanism in gardner-diamond syndrome. N Engl J Med 1977 0.81
208 Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica. Rheumatol Int 1985 0.81
209 Preferential expression of tumor necrosis factor receptor 55 (TNF-R55) on human articular chondrocytes: selective transcriptional upregulation of TNF-R75 by proinflammatory cytokines interleukin 1beta, tumor necrosis factor-alpha, and basis fibroblast growth factor. J Rheumatol 1999 0.81
210 Imaging rheumatoid arthritis joints with technetium-99m labelled specific anti-CD4- and non-specific monoclonal antibodies. Eur J Nucl Med 1994 0.81
211 MHC gene products and anticardiolipin antibodies in systemic lupus erythematosus results of a multicenter study. SLE Study Group. Autoimmunity 1992 0.81
212 Total lymphoid irradiation in patients with refractory rheumatoid arthritis. Arthritis Rheum 1985 0.81
213 Alternatively spliced mRNA molecules of the thrombospondin receptor (CD36) in human PBMC. Eur J Immunogenet 1999 0.80
214 The autologous mixed lymphocyte reaction in patients with rheumatoid arthritis. Behring Inst Mitt 1983 0.80
215 CD80 expression on monocytes in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.80
216 Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group. Rheumatol Int 1995 0.80
217 Spontaneous and antibody-dependent cellular cytotoxicity in melanoma patients and healthy control presons. Z Immunitatsforsch Exp Klin Immunol 1976 0.80
218 Severe septicaemia in a patient with polychondritis and Sweet's syndrome after initiation of treatment with infliximab. Ann Rheum Dis 2003 0.80
219 Dissociation of helper/inducer T-cell functions: immunodeficiency associated with mycobacterial histiocytosis. Clin Immunol Immunopathol 1984 0.80
220 [Follow-up in HIV-infected homosexual males with lymphadenopathy syndrome]. Klin Wochenschr 1987 0.80
221 Multiple peripheral pulmonary nodules preceding rheumatoid arthritis. Rheumatol Int 1987 0.80
222 Spontaneous suppressor cell activity in the peripheral blood of patients with malignant and chronic inflammatory bowel diseases. Clin Exp Immunol 1984 0.80
223 Amelioration of type II collagen induced arthritis in rats by treatment with sodium diethyldithiocarbamate. J Rheumatol 1999 0.80
224 Antibodies against p24 of HIV-1 in patients with systemic lupus erythematosus? Viral Immunol 1992 0.80
225 Phorbol ester enhances both interleukin 2 receptor expression and immunoglobulin secretion in human Epstein-Barr virus-immortalized B cells. Eur J Immunol 1986 0.80
226 Co-stimulation of IL-2 production by CD28 is independent of tyrosine-based signaling motifs in a murine T cell hybridoma. Eur J Immunol 2000 0.80
227 Preferential recognition of specific DNA motifs by anti-double-stranded DNA autoantibodies. Eur J Immunol 1995 0.80
228 A new spectrophotometric assay for enzymes of purine metabolism. I. Determination of xanthine oxidase activity. Enzyme 1979 0.80
229 Symptomatic bone lesion of the tibia head as onset manifestation of sarcoidosis. J Rheumatol 1999 0.79
230 UVB-irradiated T-cells undergoing apoptosis lose L-selectin by metalloprotese-mediated shedding. Int J Radiat Biol 2000 0.79
231 Persistent depletion of CD4+ T cells and inversion of the CD4/CD8 T cell ratio induced by anti-CD4 therapy. J Rheumatol 1992 0.79
232 Lead induced anaemia due to traditional Indian medicine: a case report. Occup Environ Med 1999 0.79
233 [Auto-immune diseases of the skeletal muscle-system. Immune-pathogenetic mechanisms in myasthenia gravis and polymyositis (author's transl)]. Immun Infekt 1975 0.79
234 MHC associations of autoantibodies against recombinant Ro and La proteins in systemic lupus erythematosus. Results of a multicenter study. SLE Study Group. Rheumatol Int 1992 0.79
235 Apoptosis of the teratocarcinoma cell line Tera-1 leads to the cleavage of HERV-K10gag proteins by caspases and/or granzyme B. Scand J Immunol 2002 0.79
236 [Monoclonal antibodies in clinical diagnosis and therapy]. Fortschr Med 1985 0.79
237 Human CD4 modulation in vivo induced by antibody treatment. Clin Immunol Immunopathol 1993 0.79
238 Patient-specific heterogeneity of antinuclear antibodies as revealed by an isoelectric focusing immunoblot system. Scand J Immunol 1987 0.79
239 Biased TCR repertoire in HIV-1-infected patients due to clonal expansion of HIV-1-reverse transcriptase-specific CTL clones. J Immunol 1999 0.79
240 Intraarticular T lymphocytes in monoarticular and oligoarticular inflammatory joint diseases. Normal subset distribution and less numbers of activated T cells indicate major differences as compared to rheumatoid arthritis. J Rheumatol 1986 0.79
241 Rheumatoid non-lymphoid synovial cells and the induction of mixed leukocyte reactions. Low-density preparations containing Ia+ macrophages and dendritic cells are less stimulatory than peripheral blood non-T cells. Rheumatol Int 1984 0.78
242 The role of T cells and the effect of hydrocortisone on interleukin-4-induced IgE synthesis by non-T cells. Clin Exp Immunol 1992 0.78
243 Stimulation of rheumatoid synovial and blood T cells and lines by synovial fluid and interleukin-2: characterization of clones and recognition of a co-stimulatory effect. Rheumatol Int 1990 0.78
244 Adhesion of human T lymphocytes to endothelial cells isolated from the umbilical vein: II. Enhanced binding of in vitro activated T lymphocytes. Immunobiology 1987 0.78
245 Expansion of a B-lymphocyte clone producing IgM auto-antibodies encoded by a somatically mutated VHI gene in the spleen of an autoimmune patient. Rheumatol Int 1994 0.78
246 Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol Int 1997 0.78
247 Human peripheral blood "null-lymphocytes", a highly enriched pool for granulocytic stem cells (CFU-C). Z Immunitatsforsch Immunobiol 1977 0.78
248 Synthetic glucocorticoids potentiate IgE synthesis. Influence of steroid and nonsteroid hormones on human in vitro IgE secretion. Allergy 1994 0.78
249 C3-containing serum immune complexes in patients with systemic lupus erythematosus: correlation to disease activity and comparison with other rheumatic diseases. Rheumatol Int 1989 0.78
250 Preservation of the helper and suppressor/cytotoxic T-lymphocyte phenotype in continuous culture. Eur J Immunol 1984 0.78
251 Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma? J Urol 2002 0.78
252 [Demonstration of acetylcholine receptor antibodies in the serum of myasthenia gravis patients applying affinity chromatographically purified human acetylcholine receptor preparations (author's transl)]. Klin Wochenschr 1979 0.78
253 Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum 1998 0.78
254 T cell regulation and T cell clones in relation to synovial inflammation. Springer Semin Immunopathol 1989 0.78
255 Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis. Clin Exp Rheumatol 2009 0.78
256 Proliferation and interferon production in whole blood samples and isolated lymphocyte preparations. J Interferon Res 1985 0.77
257 [The quality of life of tumor patients as a multidimensional concept]. Z Psychosom Med Psychoanal 1993 0.77
258 Lupus autoantibodies to double-stranded DNA cross-react with ribosomal protein S1. J Immunol 1996 0.77
259 Chicken and egg in autoimmunity and joint inflammation. Trends Immunol 2001 0.77
260 A new spectrophotometric assay for enzymes of purine metabolism. III. Determination of purine nucleoside phosphorylases. Enzyme 1980 0.77
261 99m-Tc-HMPAO-SPECT in diagnosis of early cerebral vasculitis. Rheumatol Int 1996 0.77
262 In vitro activation of peripheral mononuclear cells by zinc in HIV-infected patients and healthy controls. Clin Exp Immunol 1992 0.77
263 Differential immunological response of patients with rheumatoid arthritis towards two different Epstein-Barr virus strains: inhibition of interleukin-1 release by the B95-8, but not the P3HR-1 virus strain. Rheumatol Int 1989 0.77
264 Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol 1996 0.77
265 Are retroviruses involved in the pathogenesis of SLE? Evidence demonstrated by molecular analysis of nucleic acids from SLE patients' plasma. Rheumatol Int 1989 0.77
266 Etiopathogenesis of systemic lupus erythematosus. Int Arch Allergy Immunol 2000 0.77
267 Where is biological therapy going? Arthritis Res 2000 0.77
268 Immunoglobulin allotypes in systemic lupus erythematosus--results of a central European multicenter study. SLE Study Group. Exp Clin Immunogenet 1991 0.77
269 Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996 0.77
270 Estimation of T- and K-cell activity in the peripheral blood of sarcoidosis patients. Ann N Y Acad Sci 1976 0.77
271 DQB1 promoter sequence variability and linkage in caucasoids. Hum Immunol 1996 0.77
272 [New therapy developments in rheumatoid arthritis]. Z Rheumatol 2001 0.76
273 Novel autoantibodies against muscle-cell membrane proteins in patients with myositis. Arthritis Rheum 1996 0.76
274 Activated neutrophils as effector cells for bispecific antibodies. Cancer Immunol Immunother 1998 0.76
275 Poly(ADP-ribose) polymerase polymorphisms are not a genetic risk factor for systemic lupus erythematosus in German Caucasians. J Rheumatol 2000 0.76
276 Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS. Infection 1999 0.76
277 Human granulocyte colony stimulating factor: effects on human long-term bone marrow cultures. Blood Cells 1988 0.76
278 Determination of specific IgE and IgG serum antibodies during immunotherapy in hay fever patients by RAST. Z Immunitatsforsch Immunobiol 1977 0.76
279 Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1999 0.76
280 Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with indinavir. Clin Infect Dis 1997 0.76
281 [Significance of ultraviolet light in the pathogenesis of systemic lupus erythematosus: case report and discussion of the literature]. Z Rheumatol 1992 0.76
282 Human peripheral Nullymphocytes: ultrastructural aspects of the "K" cell effect against a melanoma target cell. Biomedicine 1979 0.76
283 [The role of cytokines and growth factors in rheumatoid joint destruction]. Z Rheumatol 1992 0.76
284 [Immunosuppressive therapeutic modalities in chronic polyarthritis]. Internist (Berl) 1997 0.76
285 Microchimerism after liver transplantation: prevalence and methodological aspects of detection. Transplantation 1998 0.76
286 Clonal growth of functionally normal and deficient neutrophils from the bone marrow of a patient with variant chronic granulomatous disease. Lack of reconstitution of oxidative burst defect by G-CSF, GM-CSF, and IFN-gamma in vitro. Ann Hematol 1993 0.76
287 [Prostaglandin E2, interleukin 1 and gamma interferon production of mononuclear cells of patients with inflammatory and degenerative joint diseases]. Z Rheumatol 1989 0.76
288 The serine proteinase inhibitor antileukoproteinase specifically accumulates in normal but not in arthritic cartilage. J Rheumatol 1997 0.76
289 Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000). Ann Rheum Dis 2000 0.76
290 Stimulatory response towards the 65 kDa heat shock protein and other mycobacterial antigens in patients with rheumatoid arthritis. J Rheumatol 1991 0.76
291 Evidence for direct anti-heparin-sulphate reactivity in sera of SLE patients. Rheumatol Int 1994 0.75
292 Advances in targeted therapies XII. Preface. Ann Rheum Dis 2011 0.75
293 [Autologous replantation of spleen particles--an established procedure? An opinion]. Chirurg 1985 0.75
294 [Manifestation of neuro-Behçet disease in cyclosporin A therapy]. Z Rheumatol 1997 0.75
295 Different patterns of antigen-induced histamine release during immunotherapy in insect venom and pollen allergy. Agents Actions 1986 0.75
296 A soluble form of the human transferrin receptor is released by activated lymphocytes in vitro. Clin Exp Immunol 1993 0.75
297 Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency. Ann Rheum Dis 2006 0.75
298 Influence of continuous-flow blood separator leucophoresis on in vitro functions of human lymphocytes. Clin Exp Immunol 1978 0.75
299 [Virus-induced arthritis]. Z Rheumatol 1996 0.75
300 The nonspecific clearance function of the reticuloendothelial system in patients with immune complex mediated diseases before and after therapeutic plasmapheresis. Rheumatol Int 1985 0.75
301 The effect of Bordetella pertussis vaccine on the development of experimental thyroiditis in rats immunized by the intra-lymph node route or into a hind footpad. Clin Exp Immunol 1969 0.75
302 The effect of anti-lymphocytic antibody on the development of experimental thyroiditis in rats induced by the intra-lymph node injection of rat thyroglobulin in Freund's complete adjuvant. Immunology 1971 0.75
303 [Human anti-murine immunoglobulin antibodies as disturbing factors in TSH determination]. Klin Wochenschr 1991 0.75
304 [Quantitative determination of IgG-antiglobulins in the serum of patients with chronic polyarthritis and other disorders]. Verh Dtsch Ges Inn Med 1975 0.75
305 Biological activity of the pure thymus protein, LSHr. Ann N Y Acad Sci 1979 0.75
306 Isolation of human anti-idiotypes broadly cross reactive with anti-dsDNA antibodies from patients with Systemic lupus erythematosus. Scand J Immunol 2001 0.75
307 The comparison of different rosette assay systems for the determination of T-lymphocytes in patients with solid malignant tumors. Z Immunitatsforsch Immunobiol 1978 0.75
308 Determination of complement activating circulating immune complexes and an example for antigen specific immune complex assays. J Clin Lab Immunol 1986 0.75
309 [25-year-old patient with pancytopenia]. Internist (Berl) 1995 0.75
310 Early T cell differentiated chronic myeloid leukemia blast crisis with rearrangement of the breakpoint cluster region but not of the T cell receptor beta chain genes. Blood 1987 0.75
311 Monoclonal antibodies monospecific to single-chain urokinase-type plasminogen activator (scu-PA). Hybridoma 1991 0.75
312 [Cytokines and anti-cytokine therapy in rheumatoid arthritis]. Internist (Berl) 2001 0.75
313 [Creatine-kinase-inhibiting factors in the serum of patients with myasthenia gravis]. Verh Dtsch Ges Inn Med 1974 0.75
314 Paraneoplastic syndrome, infection or arthritis: Difficulties in diagnosis. Int J Clin Pract 2006 0.75
315 A new approach to the molecular characterization of the c-ANCA antigen in Wegener's granulomatosis. Adv Exp Med Biol 1993 0.75
316 Induction of apoptosis reduces immunogenicity of human T-cell lines in mice. Scand J Immunol 1998 0.75
317 Basic mechanisms in rheumatoid arthritis: the role of T lymphocytes in rheumatoid synovitis. Adv Prostaglandin Thromboxane Leukot Res 1994 0.75
318 Cellular immune response to Borrelia burgdorferi in patients with Lyme borreliosis. Behring Inst Mitt 1991 0.75
319 [Immunologic methods]. Verh Dtsch Ges Inn Med 1985 0.75
320 Synovial fluid involvement in null cell acute lymphoblastic leukemia diagnosed with monoclonal antibodies. J Rheumatol 1988 0.75
321 [Cytokines and mediators as therapeutic approaches]. Internist (Berl) 1999 0.75
322 Graft-versus-host-like mucocutaneous eruptions with serological features of paraneoplastic pemphigus and systemic lupus erythematosus in a patient with non-Hodgkin's lymphoma. Dermatology 1998 0.75
323 Interleukin-2 production in peripheral blood mononuclear cells of patients with gastrointestinal tumors. J Clin Lab Immunol 1984 0.75
324 Apoptotic UV-irradiated lymphocytes undergo protease mediated shedding of L-selectin in vitro. Transfus Apher Sci 2001 0.75
325 Interferon production in the human mixed lymphocyte culture. Transplantation 1981 0.75
326 [Long-term remission after i.v. immunoglobulin therapy in acquired antihemophilic factor hemophilia with systemic lupus erythematosus]. Z Rheumatol 1991 0.75
327 Nelfinavir associated with peripheral neuropathy in an HIV-infected patient. Infection 1998 0.75
328 Induction of a lymphotoxin-like mediator in peripheral blood and synovial fluid lymphocytes by incubation with synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1981 0.75
329 Characterization of a 58- and a 78-kD monocytic membrane protein with affinity to the acetylcholine receptor in myasthenia gravis patients. Scand J Immunol 1994 0.75
330 [The pathogenesis of myasthenia gravis as an immunological problem]. Klin Wochenschr 1970 0.75
331 Physiochemical and immunological properties of acetylcholine receptors from human muscle. Mol Cell Biochem 1984 0.75
332 The estimation of circulating immune complexes, C3d, and anti-ds-DNA-antibody serum levels in the monitoring of therapeutic plasmapheresis in a patient with systemic lupus erythematosus. A case report. Clin Exp Rheumatol 1985 0.75
333 Active immunization against hepatitis B: immunogenicity study in homosexual men. Zentralbl Bakteriol Mikrobiol Hyg A 1985 0.75
334 [Manifestation of AIDS in HIV infected homosexual males with lymphadenopathy syndrome]. Klin Wochenschr 1989 0.75
335 Advances in targeted therapies X. Preface. Ann Rheum Dis 2008 0.75
336 [HIV-1 antigenemia and T-cell activation in HIV-1 infected patients]. Klin Wochenschr 1990 0.75
337 In vitro induction of E-rosette formation in human bone marrow cells by the thymic proteins LSHr and LSHh. Immunopharmacology 1979 0.75
338 A highly sensitive quantitative bioassay for human granulocyte-macrophage colony-stimulating factor. Exp Hematol 1990 0.75
339 [Regulation of T-cell activation by CD28 and CTLA-4]. Med Klin (Munich) 1998 0.75
340 [Superior vena cava syndrome: Catheter association as a rare cause]. Dtsch Med Wochenschr 2006 0.75
341 Intralymphatic interleukin 2 treatment in patients with acquired immunodeficiency syndrome: preliminary experience in three cases. Immunobiology 1986 0.75
342 IGM-containing immune complexes and antiphospholipid antibodies in patients with Sneddon's syndrome. Rheumatol Int 1989 0.75
343 Studies on the pathogenesis of Aleutian disease of mink. X. Demonstration of immune complexes by the 125I-C 1 q binding test after experimental infection. Zentralbl Veterinarmed B 1980 0.75
344 Establishment and characterization of a granulocyte-macrophage colony-stimulating factor-dependent human myeloid cell line. Blood 1990 0.75
345 Immune complex glomerulonephritis of mink with Aleutian disease. Contrib Nephrol 1980 0.75
346 [Colony-stimulating activity in urine and serum in a child with cyclic neutropenia]. Blut 1976 0.75
347 Serum anti-immunoglobulins in multiple myeloma and benign monoclonal hyperglobulinemia. Clin Immunol Immunopathol 1980 0.75
348 Autologous PBPCT in a patient with lymphoma and Sjögren's syndrome: complete remission of lymphoma without control of the autoimmune disease. Bone Marrow Transplant 1998 0.75
349 Advances in targeted therapies XIV. Ann Rheum Dis 2013 0.75
350 T cell clones in rheumatoid arthritis (RA). Scand J Rheumatol Suppl 1988 0.75
351 Epitope-specific signaling through CD45 on T lymphocytes leads to cAMP synthesis in monocytes after ICAM-1-dependent cellular interaction. Eur J Immunol 1998 0.75
352 [LE diagnosis made easy]. MMW Munch Med Wochenschr 1978 0.75
353 [Physiology and physiopathology of the immune system]. Internist (Berl) 1984 0.75
354 Inflammation: crucial areas and clinical relevance. Agents Actions Suppl 1982 0.75
355 [Therapy of inflammatory rheumatic diseases: from current practice standards to future]. Internist (Berl) 2001 0.75
356 Human granulocyte colony stimulating factor. Blut 1987 0.75
357 [Significance of serum antibodies against dsDNA in the diagnosis of patients with systemic lupus erythematosus (proceedings)]. Z Rheumatol 1976 0.75
358 [Immunologic methods in the differential diagnosis of collagen diseases]. Med Welt 1975 0.75
359 Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection. J Acquir Immune Defic Syndr 1999 0.75
360 [Suppression of monocyte-macrophage activation by anti-CD4 therapy in patients with chronic polyarthritis]. Immun Infekt 1991 0.75
361 [Pathogenesis of rheumatoid arthritis]. Med Klin (Munich) 1997 0.75
362 Advances in targeted therapies XIII. Ann Rheum Dis 2012 0.75
363 Improved in vitro diagnosis of allergy to Alternaria tenius and Cladosporium herbarum. Allergy 1987 0.75
364 [Determination of colony stimulating activity in a child with cyclic neutropenia]. Monatsschr Kinderheilkd 1976 0.75
365 Clinical research in the Federal Republic of Germany. Immunol Today 1989 0.75
366 Flow cytometric discrimination between viable neutrophils, apoptotic neutrophils and eosinophils by double labelling of permeabilized blood granulocytes. J Immunol Methods 2000 0.75
367 [Mediastinal spreading and aortic insufficiency]. Med Klin (Munich) 1997 0.75
368 Mitogen-induced gamma interferon production in peripheral blood lymphocytes from patients with colorectal tumors. Immunobiology 1984 0.75
369 [Salicylic acid in the urine in recurrent stomach and duodenal ulcers?]. Dtsch Med Wochenschr 1983 0.75
370 [Immunologic and electron microscopic findings in an unusual case of Whipple's disease]. Klin Wochenschr 1985 0.75
371 Origin of anti-DNA autoantibodies in SLE. Lupus 1994 0.75
372 [Treatment of immunologic diseases using plasma separation. Proven and unproved indications]. Fortschr Med 1984 0.75
373 Monoclonal antibodies EBU-141 (CDw75) and EBU-65 allow reliable distinction between mature and pre-B-cell tumors in suspension and on tissue sections. Ann Hematol 1991 0.75
374 [Polyneuropathy in allergic granulomatosis and angiitis (Churg-Strauss syndrome)]. Nervenarzt 1986 0.75
375 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res 1995 0.75
376 [Gastritis and thoracic pain. Churg-Strauss vasculitis]. Med Klin (Munich) 1998 0.75
377 [Recent developments in high-dose immunoglobulin therapy: therapeutic plasma exchange, autoimmune diseases]. Beitr Infusionther Klin Ernahr 1982 0.75
378 Monoclonal antibodies directed against the rev protein of human immunodeficiency virus type 1. Mol Cell Probes 1990 0.75
379 Letter: Sézary syndrome. Lancet 1974 0.75
380 Predominance of T-lymphocytes with a high-affinity receptor for sheep red blood cells in the synovial fluid of patients with rheumatoid arthritis. A short communication. Z Rheumatol 1981 0.75
381 Lack of serologic evidence for involvement of human herpesvirus 8 in autoimmune diseases. Arthritis Rheum 1997 0.75
382 [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis]. Klin Wochenschr 1984 0.75
383 Ultrasound in the evaluation of an unusual periarticular soft tissue tuberculosis. J Clin Rheumatol 1998 0.75
384 Treatment of rheumatoid arthritis in the third millennium. Scand J Rheumatol 2001 0.75
385 Comparison and standardization of measurement of anti-acetylcholine receptor antibody between laboratories. Autoimmunity 1988 0.75
386 A new spectrophotometric assay for enzymes of purine metabolism. II. Determination of guanase activity. Enzyme 1979 0.75
387 [Immunologic therapeutic approaches in malignant diseases, especially in pancreatic tumors]. Verh Dtsch Ges Pathol 1987 0.75
388 New therapeutic approaches in autoimmune rheumatic diseases, with special emphasis on rheumatoid arthritis. Br J Rheumatol 1995 0.75
389 Autoantibodies to double-stranded (ds)DNA immunoprecipitate 18S ribosomal RNA by virtue of their interaction with ribosomal protein S1 and suppress in vitro protein synthesis. Clin Exp Immunol 1996 0.75
390 [Intravenous administration of immunoglobulins in systemic lupus erythematosus: review of the literature and initial clinical experiences]. Infusionsther Transfusionsmed 1993 0.75
391 [High-dose immunoglobulin therapy of rheumatoid arthritis]. Infusionsther Transfusionsmed 1993 0.75
392 Analysis of leukemic cells with monoclonal antibodies in acute myelomonocytic leukemia suggests abnormality at an early differentiation stage in certain cases. Haematol Blood Transfus 1985 0.75
393 [Role of cytokines and growth factors in joint destruction processes]. Rev Med Chil 1992 0.75
394 Immunological studies in homosexual men with unexplained lymphadenopathy. Eur J Clin Microbiol 1984 0.75
395 Advances in targeted therapies XI. Ann Rheum Dis 2010 0.75
396 [Comparison of rheumatoid test procedures--value and critical interpretation of sensitivity and specificity and their effect on pre-test and post-test probability]. Z Rheumatol 1996 0.75
397 Adhesion of human T lymphocytes to endothelial cells isolated from the umbilical vein: I. Similar binding patterns of normal and rheumatoid T cells. Immunobiology 1987 0.75
398 [Presentation of the Erlangen Competence Center]. Z Rheumatol 2001 0.75
399 Pulmonary sarcoidosis associated with acquired humoral and cellular immunodeficiency. Clin Immunol Immunopathol 1985 0.75
400 [Churg-Strauss syndrome. Seldom seen or only seldom diagnosed?]. Dtsch Med Wochenschr 1988 0.75
401 [An unusual case of Heberden arthrosis in a young man]. Z Rheumatol 1999 0.75
402 [Thymus pathology in diseases with disturbed immune reactions (review)]. Z Immunitatsforsch Allerg Klin Immunol 1970 0.75
403 [Effector function of acute leukemias in "spontaneous" (SCMC) and antibody dependent cellular cytotoxicity-tests (ADCC) (author's transl)]. Klin Wochenschr 1978 0.75
404 Small DNA fragments isolated from human T-cell clones are enriched in sequences involved in DNA bending. Cell Death Differ 1996 0.75
405 [Total lymphoid irradiation in chronic polyarthritis--a new therapeutic concept]. Strahlenther Onkol 1986 0.75
406 [Epstein-Barr-virus-antibodies and lymphocytotoxic serum-antibodies in patients with sarcoidosis]. Klin Wochenschr 1972 0.75
407 The binding of different lectins on peripheral blood mononuclear cells from patients with chronic inflammatory and malignant diseases. Immunobiology 1983 0.75
408 [Functional tests of the immune system]. Internist (Berl) 1979 0.75
409 [Immunologic findings in homosexual males with generalized lymphadenopathy. Prodromal state of acquired immunodeficiency syndrome?]. Klin Wochenschr 1983 0.75
410 [Immunological characterization of unusual plasmacytic tumor cells in a disseminated non-Hodgkin's lymphoma]. Immun Infekt 1984 0.75
411 Therapy for HIV-1-related nephritis with zidovudine. AIDS 1990 0.75
412 [Australia antigen in chronic aggressive hepatitis and liver cirrhosis. Its significance for the etiology and pathogenesis of chronic inflammatory liver diseases]. Dtsch Med Wochenschr 1972 0.75
413 Clinical autoimmunity. Immunol Today 1989 0.75
414 Cimetidine and psoriatic arthritis. Arch Dermatol 1983 0.75
415 Coexistence of severe palmo-plantar Dupuytren's contracture, Raynaud's phenomenon and digital joint erosions. Rheumatol Int 1985 0.75
416 Immunological and functional properties of the acetylcholine receptor expressed on the human cell line TE671. Eur J Clin Chem Clin Biochem 1993 0.75
417 Proliferative responses to human cytomegalovirus in lymphocyte cultures of male homosexuals. J Clin Lab Immunol 1985 0.75
418 Workshop summary: the emerging role of biologicals in the treatment of patients with newly diagnosed rheumatoid arthritis. Rheumatology (Oxford) 1999 0.75
419 A new spectrophotometric method for the determination of 5'-nucleotidase. J Clin Chem Clin Biochem 1980 0.75
420 Idiotypic determinants and antiglobulins in multiple myeloma. Haematol Blood Transfus 1977 0.75
421 [An unusual case of rectal-sigmoid varicose veins in portal vein thrombosis]. Rontgenpraxis 1994 0.75
422 [Pathogenesis of partial neuromuscular block in experimental myasthenia gravis]. Verh Dtsch Ges Inn Med 1973 0.75
423 [Immune complexes in allergies: evidence of IgE-containing immune complexes in Churg-Strauss vasculitis]. Klin Wochenschr 1986 0.75
424 [Use of an improved transmission ultrasound camera for diagnosis of rheumatic joint diseases]. Z Rheumatol 1993 0.75
425 Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production. Klin Wochenschr 1987 0.75
426 Inflammatory arterial stenosis: followup with color Doppler sonography. Arthritis Rheum 2000 0.75
427 [BCG granulomatosis, a complication of vaccination, induced through a limited cellular defect of the immune system]. Monatsschr Kinderheilkd 1975 0.75
428 [Systemic lupus erythematosus and pregnancy]. Z Rheumatol 1992 0.75
429 Leflunomide: an immunosuppressive drug with multiple effects on T cell function. Mod Rheumatol 2002 0.75
430 Biological agents in rheumatoid arthritis: which ones could be used in combination? BioDrugs 1998 0.75
431 [Pathomechanisms of tissue damage exemplified by collagenoses]. Verh Dtsch Ges Inn Med 1987 0.75
432 Rat antigen-induced arthritis: cartilage alterations assessed with iodine-123-antileukoproteinase. J Nucl Med 1998 0.75
433 A human monoclonal IgM kappa cold agglutinin recognizing oligosaccharides with immunodominant sialyl groups preferentially at the blood group M-specific peptide backbone of glycophorins: anti-PrM. Vox Sang 1986 0.75
434 A new spectrophotometric assay for enzymes of purine metabolism. IV. Determination of adenosine deaminase. Enzyme 1980 0.75
435 Thrombomodulin in systemic lupus erythematosus: association with clinical and laboratory parameters. Rheumatol Int 1999 0.75
436 [Significance of serum antibodies against ds-DNA for diagnosis of patients with systemic lupus erythematosus]. Verh Dtsch Ges Rheumatol 1976 0.75
437 [Effect of histamine-blocking substances on mitogen-induced lympho proliferation in rheumatic diseases]. Z Rheumatol 1984 0.75
438 The effect of serum and allogeneic antiglobulin preparations on the mitogenic reactivity of peripheral blood lymphocytes from patients with rheumatoid arthritis. Z Rheumatol 1979 0.75
439 Impairment of genomic DNA binding to a putative dysfunctional receptor on erythrocytes independent of complement and antibodies in systemic lupus erythematosus. Virchows Arch 2000 0.75
440 Differential effects of transferrin receptor antibodies on growth and receptor expression of human lymphocytic and myelocytic cell lines. Eur J Haematol 1994 0.75
441 Chronic lymphocytic leukemia cells induce non-T cells to produce IgE in the presence of interleukin-4. J Clin Immunol 1993 0.75
442 Failure to immortalize human "null" cells by Epstein Barr virus (EBV) "in vitro". Hamatol Bluttransfus 1976 0.75
443 Lambert-Eaton myasthenic syndrome and undifferentiated connective tissue disease in a patient carrying the 8.1 ancestral haplotype. Ann Rheum Dis 2005 0.75
444 Interleukin-4-induced IgG subclass and IgE secretion by mononuclear cells from atopic donors. Int Arch Allergy Appl Immunol 1991 0.75